Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-GPC3 CAR-T cells (Xinqiao Hospital)
- Development stage
- Unknown
- Lead developer
- Xinqiao Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
anti-GPC3 CAR-T cells (Xinqiao Hospital) is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target Glypican-3 (GPC3), an oncofetal antigen highly expressed in hepatocellular carcinoma (HCC) but with limited expression in normal adult tissues. The CAR construct utilized by Xinqiao Hospital consists of an anti-GPC3 single-chain variable fragment (scFv) for antigen recognition, a 4-1BB (CD137) costimulatory domain to enhance T-cell persistence and metabolic fitness, and a CD3ζ signaling domain for T-cell activation. Additionally, the construct incorporates a truncated epidermal growth factor receptor (tEGFR), which serves as a selection marker during manufacturing and a potential safety switch for antibody-mediated depletion. In clinical trials, this therapy is often administered following lymphodepleting chemotherapy (fludarabine and cyclophosphamide) and in combination with transcatheter arterial chemoembolization (TACE) to treat patients with advanced, GPC3-positive HCC.
- Other names
- anti-GPC3 CAR-Tanti-GPC-3 CAR-Tanti-GPC 3 CAR-TGPC3-targeted CAR-T cellsGPC-3-targeted CAR-T cellsGPC 3-targeted CAR-T cells
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on anti-GPC3 CAR-T cells (Xinqiao Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-GPC3 CAR-T cells (Xinqiao Hospital).